PE20090816A1 - Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 - Google Patents

Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3

Info

Publication number
PE20090816A1
PE20090816A1 PE2008000804A PE2008000804A PE20090816A1 PE 20090816 A1 PE20090816 A1 PE 20090816A1 PE 2008000804 A PE2008000804 A PE 2008000804A PE 2008000804 A PE2008000804 A PE 2008000804A PE 20090816 A1 PE20090816 A1 PE 20090816A1
Authority
PE
Peru
Prior art keywords
receptors
alkyl
binding agents
pirrolo
acetylpiperazin
Prior art date
Application number
PE2008000804A
Other languages
English (en)
Inventor
Malken Bayrakdarian
Cristophe Buon
Louis-David Cantin
Yun-Jin Hu
Xuehong Luo
Santhakumar Vijayaratnam
Miroslaw Tomaszewski
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39943763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090816(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090816A1 publication Critical patent/PE20090816A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRROLOPIRIMIDINONA DE FORMULA (I), DONDE R1 Y R2 SON H, ALQUILO C1-C6-C(=O)-, ALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(4-ACETILPIPERAZIN-1-IL)-6-ISOPROPIL-4-(1,2,3,4-TETRAHIDRONAFTALEN-1-ILAMINO)-5,6-DIHIDRO-7H-PIRROLO[3,4-d]PIRIMIDIN-7-ONA, 2-(4-ACETILPIPERAZIN-1-IL)-4-[CICLOPENTIL(4-FLUOROBENCIL)AMINO]-6-ISOPROPIL-5,6-DIHIDRO-7H-PIRROLO[3,4-d]PIRIMIDIN-7-ONA, 2-(4-ACETILPIPERAZIN-1-IL)-4-{[1-(4-ISOBUTILFENIL)ETIL]AMINO}-6-ISOPROPIL-5,6-DIHIDRO-7H-PIRROLO[3,4-d]PIRIMIDIN-7-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES P2X3 Y SON UTILES EN EL TRATAMIENTO DEL DOLOR
PE2008000804A 2007-05-08 2008-05-08 Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 PE20090816A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91658807P 2007-05-08 2007-05-08

Publications (1)

Publication Number Publication Date
PE20090816A1 true PE20090816A1 (es) 2009-07-25

Family

ID=39943763

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000804A PE20090816A1 (es) 2007-05-08 2008-05-08 Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3

Country Status (16)

Country Link
US (1) US20090099195A1 (es)
EP (1) EP2155751A1 (es)
JP (1) JP2010526138A (es)
KR (1) KR20100017688A (es)
CN (1) CN101687875A (es)
AR (1) AR066475A1 (es)
AU (1) AU2008246351A1 (es)
BR (1) BRPI0811436A2 (es)
CA (1) CA2686707A1 (es)
CL (1) CL2008001335A1 (es)
MX (1) MX2009011997A (es)
PE (1) PE20090816A1 (es)
RU (1) RU2009140469A (es)
TW (1) TW200846001A (es)
UY (1) UY31068A1 (es)
WO (1) WO2008136756A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0921317A2 (pt) * 2008-11-06 2017-06-06 Astrazeneca Ab composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP5692747B2 (ja) 2009-02-13 2015-04-01 塩野義製薬株式会社 新規トリアジン誘導体およびそれを含有する医薬組成物
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TW201121957A (en) 2009-11-18 2011-07-01 Astrazeneca Ab Benzoimidazole compounds and uses thereof
CN102939282B (zh) 2010-04-16 2015-12-02 Ac免疫有限公司 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
WO2011133659A2 (en) * 2010-04-20 2011-10-27 Emory University Inhibitors of hif and angiogenesis
EP2604595B1 (en) 2010-08-10 2016-03-16 Shionogi&Co., Ltd. Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
EP2604260B1 (en) * 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
US9381260B2 (en) 2011-12-27 2016-07-05 Emory University Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
CA2898665C (en) 2013-01-31 2021-02-16 Neomed Institute Imidazopyridine compounds and their use as p2x purinoreceptor modulators
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
WO2016088838A1 (ja) * 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
LT3230281T (lt) 2014-12-09 2021-07-12 Bayer Aktiengesellschaft 1,3-tiazol-2-ilu pakeisti benzamidai
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017209267A1 (ja) * 2016-06-03 2017-12-07 塩野義製薬株式会社 プリン誘導体
JP6856471B2 (ja) * 2017-01-04 2021-04-07 株式会社トクヤマ ラクトン化合物の製造方法、および該ラクトン化合物を使用したビオチンの製造方法
US11365194B2 (en) 2017-09-27 2022-06-21 Kagoshima University Analgesic drug using PAC1 receptor antagonistic drug
CN111527090B (zh) * 2017-10-27 2023-05-26 拜耳公司 作为p2x3抑制剂的吡唑并-吡咯并-嘧啶-二酮衍生物
CN107778282B (zh) * 2017-11-03 2020-04-10 中山大学 喹啉-吲哚衍生物及其在制备治疗阿尔茨海默病的药品中的应用
JP2021523092A (ja) * 2018-03-21 2021-09-02 ピラマル・ファーマ・リミテッドＰｉｒａｍａｌ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ アルファ−（ジアリールメチル）アルキルアミンの改良された不斉合成
WO2020175134A1 (ja) 2019-02-27 2020-09-03 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痒薬
WO2021058018A1 (en) * 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
WO2021068698A1 (en) * 2019-10-12 2021-04-15 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
CN113135924B (zh) * 2020-01-19 2024-04-26 广东东阳光药业股份有限公司 嘧啶衍生物及其在药物中的应用
WO2021173923A1 (en) * 2020-02-28 2021-09-02 Erasca, Inc. Pyrrolidine-fused heterocycles
US20230151013A1 (en) * 2020-03-13 2023-05-18 Astrazeneca Ab Fused pyrimidine compounds as kcc2 modulators
EP4147701A1 (en) 2020-05-08 2023-03-15 Kagoshima University Antidepressant/anxiolytic drug in which pac1 receptor antagonist is used
WO2022058344A1 (en) 2020-09-18 2022-03-24 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
WO2022067462A1 (en) * 2020-09-29 2022-04-07 Beigene (Beijing) Co., Ltd. Process for preparing inhibitors of kras g12c
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058914A1 (en) * 2000-12-22 2004-03-25 Takayuki Doi Combination drugs
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases

Also Published As

Publication number Publication date
MX2009011997A (es) 2009-11-19
US20090099195A1 (en) 2009-04-16
CN101687875A (zh) 2010-03-31
BRPI0811436A2 (pt) 2014-12-16
CA2686707A1 (en) 2008-11-13
WO2008136756A1 (en) 2008-11-13
CL2008001335A1 (es) 2008-11-14
TW200846001A (en) 2008-12-01
KR20100017688A (ko) 2010-02-16
AR066475A1 (es) 2009-08-19
JP2010526138A (ja) 2010-07-29
RU2009140469A (ru) 2011-06-20
UY31068A1 (es) 2009-01-05
EP2155751A1 (en) 2010-02-24
AU2008246351A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
CR7548A (es) Derivados de triazole como antagonistas del receptor de tachykinin
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
PE20170003A1 (es) Compuestos heterociclicos y usos de los mismos
PE20091095A1 (es) Moduladores de gamma secretasa
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
UY29427A1 (es) Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20091330A1 (es) Derivados de 4-aminopirimidina como antagonistas de receptores de histamina h4
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
PE20090712A1 (es) Moduladores de la gamma secretasa
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal